Advanced Biomed Inc. (ADVB) stock

NASDAQ: ADVB Nasdaq Life Sciences Tools & Services

Advanced Biomed Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in June.

The Fundamentalytics view

Current signal Earnings running well ahead of cash (high accruals): Over the last 12 months net income exceeded operating cash flow by an amount equal to 62.7% of total assets. Earnings built on accounting accruals rather than cash have historically proved less persistent.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Advanced Biomed Inc.'s latest figures clears our strength thresholds.

Things to watch

Volatile shares. Over the past year the shares showed annualised volatility of 168% and a beta of -0.4 against the S&P 500.
Weak cash conversion. Free cash flow was -44% of net income over the last 12 months.

Price chart

1 day-9.8%
1 week-24.0%
1 month-69.2%
This year-64.5%
1 year-78.4%
S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

July 17, 2026Agreement ended

Advanced Biomed Inc. ended a material agreement

SEC 8-KRead source ↗

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Advanced Biomed Inc. valuation models and calculator

No model value for Advanced Biomed Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Advanced Biomed Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.04 times a 4.5% equity risk premium.

Value per share by model
Model	Value per share	In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings.	~$140 ~$130–$150	Left out: out of range vs price (66.71x)
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years.	—	Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns.	—	Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable.	—	Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative.	—	Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld.	—	Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Advanced Biomed Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Advanced Biomed Inc.: too few analysts cover it.

Positioning

Short interest: 1.1%
Days to cover: 0.5
Short interest, 1 month: −1%
Held by institutions: 1%
Held by insiders: 61.4%
Employees: 12

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Advanced Biomed Inc.: yearly return, monthly win rate and worst fall against the S&P 500
Calendar year	2026 to date
Return
ADVB	−65%
Industry peers (median)	+16%
S&P 500	+11%
Months that ended higher
ADVB	46%
S&P 500	46%
Largest fall from a high during the year
ADVB	−89%
S&P 500	−9%

Worst fall since March 6, 2025: 97% from March 28, 2025 to November 2, 2026. Getting back needed a 3755% gain, and the shares have not yet recovered.

Price behaviour

52-week range: $2.08 – $18.98
From 52-week high: −89.1%
vs 50-day average: −67.6%
vs 200-day average: −64.8%
Volatility (1 year): 168%
Beta vs S&P 500: -0.39

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Advanced Biomed Inc.: annual financial statements
Fiscal year	2026 Jun 2026
Income
Revenue	128
Operating income	−6,234
Net income	6,677
Diluted EPS	$5.33
Margins
Operating margin	<−999%
Net margin	>999%
Free-cash-flow margin	<−999%
Cash flow
Cash from operations	−1,947
Capital spending	0
Free cash flow	−1,947
Stock-based pay	1,734
Free cash flow after stock pay	−3,681
Balance sheet
Cash	386
Total debt	0
Net debt (negative = net cash)	−386
Diluted shares	1m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Insider trading activity

Full insider history and chart

Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders

Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

10-K Annual report October 13, 2026
8-K Current report July 17, 2026
8-K Current report July 1, 2026
8-K Current report June 30, 2026
DEF 14A Proxy statement June 4, 2026
10-Q Quarterly report May 15, 2026
8-K Current report May 1, 2026
8-K Current report April 14, 2026

Data status

When each part of this page on Advanced Biomed Inc. was last updated.

Data	Last updated	Source
Share price	November 2, 2026	Exchange closing prices
News and updates	October 31, 2026, 7:55pm ET	Company releases and SEC 8-K filings
Analyst estimates	October 31, 2026, 9:11am ET	Aggregated analyst estimates
Valuation and scores	November 3, 2026, 9:08am ET	Our models, from the filed figures

How we build and check these figures: methodology and data sources.

Advanced Biomed Inc. in brief

What does Advanced Biomed Inc. do?: Advanced Biomed Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in June.
What is Advanced Biomed Inc.'s stock ticker?: Advanced Biomed Inc. trades under the ticker ADVB on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Advanced Biomed Inc.'s market cap?: On June 30, 2026, Advanced Biomed Inc.'s market capitalisation was about $5.8M, with a price-to-earnings ratio of 0.9 and net debt of -$385,535. Market figures come from third-party market data and may be delayed.